8-K: SenesTech Reports Record Q2 Revenue & Gross Profit

SenesTech, Inc. announced record second quarter 2025 financial results, driven by 94% growth in Evolve rodent birth control product sales and improved gross profit margins.

Summary

• Record Q2 2025 revenue reached $625,000, marking a 36% increase from $459,000 in Q2 2024.
• Sales of Evolve Rodent Birth Control products grew 94% year-over-year, now accounting for 83% of total revenue.
• Gross profit margin improved to a record 65.4% in Q2 2025, up from 54.2% in Q2 2024.
• Net loss for Q2 2025 was $1.6 million, consistent with Q2 2024, but included $201,000 in one-time legal expenses and $38,000 in non-cash operating lease expense.
• Adjusted EBITDA loss continued to improve, reaching $1.4 million in Q2 2025 compared to $1.5 million in the same quarter of the prior year.
• The current cash balance as of August 5, 2025, is $11.2 million, providing an operating runway through the end of 2027 and beyond.
• The company completed its move into a new manufacturing facility in July 2025, aiming to meet growing demand and improve capacity and gross margins through automation.

Sentiment

Score: 8

Explanation: The company reported record revenue and gross profit margins, significant growth in its core Evolve product line, and improved Adjusted EBITDA. A strong cash balance provides a long operating runway. While still operating at a net loss, the operational improvements and strategic expansions are highly positive.

Positives

• Achieved record quarterly revenue of $625,000, representing a 36% year-over-year increase.
• Attained a record gross profit margin of 65.4%, a significant improvement from 54.2% in the prior year quarter.
• Evolve Rodent Birth Control product sales surged by 94% year-over-year, becoming the primary revenue driver.
• E-commerce revenue increased by 78% year-over-year, with Amazon sales showing double-digit month-over-month growth since January.
• Adjusted EBITDA loss improved to $1.4 million from $1.5 million in the comparable prior year quarter.
• A strong cash balance of $11.2 million as of August 5, 2025, provides an operating runway through the end of 2027.
• Expanded municipal pilot deployments in major cities including New York City, Chicago, Boston, Baltimore, Los Angeles County, and San Francisco.
• A strategic partnership with Bradley Caldwell resulted in 478% year-over-year growth in the Retail market vertical.
• The new manufacturing facility, operational in July 2025, is expected to enhance capacity and gross margins through automation.

Negatives

• Net loss remained at $1.6 million for Q2 2025, consistent with Q2 2024, despite significant revenue growth.
• Q2 2025 net loss included $201,000 in one-time legal expenses.
• The company continues to operate at a net loss and Adjusted EBITDA loss, indicating it has not yet achieved profitability.

Risks

• Successful commercialization of products.
• Market acceptance of products.
• Financial performance, including the ability to fund operations.
• Ability to maintain compliance with Nasdaq's continued listing requirements.
• Regulatory approval and regulation of products.
• Other factors and risks identified from time to time in SEC filings, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

Evolve Rat and Evolve Mouse products are expected to continue gaining traction among pest management professionals and consumers. Additional municipal deployments are underway or planned, with commercial launches in Australia and New Zealand anticipated later in 2025. New orders and reorders are expected in coming months from countries with signed distribution agreements. The new manufacturing facility with automated capabilities is projected to drive improvements in capacity and gross margins. The company believes it is disrupting the multi-billion-dollar rodenticide industry with a scalable, science-driven solution and is focused on revenue growth and implementing efficiencies to improve profitability metrics, positioning itself to achieve breakeven goals and meet growth potential. The mission is to provide proactive, safe, and sustainable products that seamlessly integrate into integrated pest management programs.

Management Comments

• "We delivered another quarter of record revenue and gross margins fueled by the rapid adoption of our Evolve product line and disciplined OpEx management." Joel Fruendt, CEO.
• "Our results reflect the strength of our diverse multi-channel distribution strategy, with momentum across E-commerce, city and government deployments, brick-and-mortar retail, and international partnerships." Joel Fruendt, CEO.
• "As the pioneers in rodent birth control, we are directly reducing rodent populations and reshaping the multi-billion-dollar rodenticide industry with a scalable, science-driven solution delivers proven, sustainable results." Joel Fruendt, CEO.
• "Our commitment to growth is matched by a clear on efficiency and profitability." Joel Fruendt, CEO.
• "With more than $6 million in cash at the end of the quarter, and an additional $6.3 million in gross proceeds which closed subsequent to quarter end, we are well positioned to achieve our breakeven goals and meet our growth potential." Joel Fruendt, CEO.
• "We remain focused on delivering sustainable growth and creating long-term value for our shareholders." Joel Fruendt, CEO.

Industry Context

SenesTech positions itself as a leader in fertility control for animal pest populations, specifically rodents, and the sole manufacturer of EPA-registered rodent birth control products. This establishes the company as an innovator disrupting the traditional multi-billion-dollar rodenticide industry by offering a humane, sustainable, and science-driven alternative to lethal methods. The growing adoption in municipal programs and retail indicates a broader industry shift towards more environmentally conscious and long-term pest management solutions.

Comparison to Industry Standards

• The company claims to be the "pioneers of fertility control for rodents" and the "only manufacturer of EPA-registered rodent birth control products," suggesting a unique market position with no direct, widely recognized public comparables offering the same specific product type.
• Their Evolve and ContraPest products are presented as alternatives to traditional rodenticides, which typically involve poisons or traps. The 94% growth in Evolve product sales and 478% growth in the retail market vertical suggest strong adoption compared to the slower, more established growth rates of conventional pest control methods.
• The expansion into municipal pilot deployments in major U.S. cities (New York City, Chicago, Boston, Baltimore, Los Angeles County, San Francisco) indicates a growing acceptance of their non-lethal approach, potentially setting a new standard for urban pest management compared to traditional, often less effective, large-scale poisoning campaigns.
• The improved gross profit margin of 65.4% suggests a strong unit economic model for their specialized products, which may be higher than commodity pest control products.

Legal Proceedings

• Q2 2025 net loss included $201,000 in one-time legal expenses.

Stakeholder Impact

• Shareholders: Positive impact due to record financial results, strong growth in core products, improved profitability metrics (Adjusted EBITDA), extended operating runway, and strategic expansions, potentially leading to increased shareholder value.
• Customers (Pest Management Professionals & Consumers): Increased availability and adoption of Evolve products through e-commerce, retail, and municipal programs, offering a humane and sustainable rodent control solution.
• Employees: Expansion of manufacturing facility suggests potential for job stability or growth, though not explicitly stated.
• Regulatory Authorities (EPA): Continued compliance and expansion of EPA-registered products reinforce the company's position as a responsible and innovative player in pest management.

Next Steps

• Continued gaining traction for Evolve Rat and Evolve Mouse products among pest management professionals and consumers.
• Additional municipal deployments are underway or planned.
• Commercial launch in Australia and New Zealand expected later in 2025.
• Expectation of new orders and reorders in coming months from countries with signed distribution agreements.
• Leveraging the new manufacturing facility with automated capabilities to drive improvement in capacity and gross margins.
• Focus on delivering sustainable growth and creating long-term value for shareholders.
• Achieving breakeven goals.

Key Dates

Recommendation

The company reported record revenue and gross profit margins, demonstrating strong operational execution and product market fit, particularly with the Evolve product line which saw 94% year-over-year growth. The improved Adjusted EBITDA loss and a substantial cash balance of $11.2 million, providing an operating runway through 2027, significantly de-risk the investment. Strategic expansions into municipal deployments and retail, coupled with manufacturing automation, indicate a clear path to scaling and future profitability. These factors suggest strong growth potential and a favorable investment outlook.

Keywords

Rodent control, Pest management, Fertility control, Biotechnology, Animal health, Evolve, ContraPest, EPA-registered, NASDAQ: SNES